Cart
×
2021 FUTURES: Keynote Panel
An inspiring conversation about living in the moment with a rare diagnosis.
Video
A Family Guide to Dealing With Duchenne Muscular Dystrophy
This resource presents the history of Duchenne muscular dystrophy and provides a basic understanding of the genetics, management and treatment of the diesease.
Samiya Ahmad, MD
Assistant Professor of Pediatrics, Child Neurology and Sleep Medicine | Medical Director, Comprehensive Neuromuscular Center
Baylor College of Medicine | Children's Hospital of San Antonio
Video
A Holistic View of Clinical Trials
This panel discussion provides a robust conversation about how clinical trials intersect with family life in the Duchenne community.
Video
Acceso a la Atención
Esta presentación se centra en la atención multidisciplinaria para personas con distrofia muscular de Duchenne.
Hugo Trevino, M.Ed.
Servicios para discapacitados
Universidad de Illinois
Video
Asistencia para Familias
Esta presentación se centra en la asistencia financiera para familias en los Estados Unidos de América.
Leslie Guzman
Directora de desarrollo de programas
Programa de Asistencia Familiar de Duchenne
Video
Avidity Biosiences
Advancing Exon Skipping AOCs for the Treatment of Duchenne Muscular Dystrophy
Avidity Biosciences is a biotechnology company based in La Jolla, California. At Avidity, we are driven by our mission to improve the lives of people affected by diseases with limited therapeutic options, such as Duchenne muscular dystrophy (DMD). We are doing this by realizing the broad and disruptive potential of our Antibody Oligonucleotide Conjugates (AOC™) platform. AOCs combine the specificity of monoclonal antibodies and the precision of oligonucleotides. Avidity is advancing three different exon skipping AOC drugs designed to treat the root cause of DMD in individuals who are amenable to skipping exons 44, 45 or 51. Our first program in development for the treatment of DMD is called AOC 1044 and is designed to treat individuals who are amenable to exon 44 skipping treatments. We are planning to initiate our first clinical trial with AOC 1044 by the end of 2022.
Mark Stahl, MD, PhD
Senior Medical Director, Clinical Development
Avidity Biosciences
Video
Beginning the Duchenne Journey
From FUTURES 2023
- Coping as a Caregiver
- Communicating Duchenne to your child/family
- Preparing for a bright future: play, communicate, and appropriate exercise
- Neurological concerns
- Introducing Stretching and Equipment
- Role of Social Work
- Duchenne’s Impact on Nutritional Health and Habits
Kayla Richards, LMSW
Social Worker
UT Health Austin Pediatric Neurosciences at Dell Children's
Diana Castro, MD
Associate Professor of Pediatrics, Neurology and Neurotherapeutics
University of Texas Southwestern
Kindann Fawcett, PhD
Post Doctoral Fellow
University of Arkansas for Medical Sciences
Video
Beyond Dystrophin Panel
This conference session provides insight and updates from companies whose therapies target critical aspects of the Duchenne disease process that occur alongside reductions in dystrophin.
Abby Bronson
Vice President, Patient Advocacy & External Innovation
Edgewise Therapeutics
Daniel Paulson, MD
Vice President of Clinical Development
Capricor Therapeutics
Video
Coalición Latinoamericana DMD/BMD
Esta presentación trata sobre Coalición Latinoamericana DMD / BMD y cómo apoyan a las familias en diferentes países.
Gloria Orozco
Presidenta, Coalición Latinoamericana DMD/DMB
Coalición Latinoamericana DMD/BMD
Video
